Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
Status:
Completed
Trial end date:
2017-07-05
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well tipifarnib works in treating patients with relapsed or
refractory non-Hodgkin's lymphoma. Tipifarnib may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth. Tipifarnib may be an effective treatment for
non-Hodgkin's lymphoma.